NASDAQ:SNY

Sanofi (SNY) Stock Forecast, Price & News

$53.86

+0.17 (+0.32%)

(As of 05/18/2023 ET)

Compare

Today's Range: $53.41
▼
$53.94
50-Day Range: $53.35
▼
$57.18
52-Week Range: $36.91
▼
$57.82

Volume: 1.57 million shs
Average Volume: 1.95 million shs
Market Capitalization: $135.83 billion

P/E Ratio: 19.30
Dividend Yield: 2.34%
Price Target: $94.50

Sanofi MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 75.5% Upside
$94.50 Price Target
Short Interest: Healthy
0.14% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.24
Based on 15 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 8.48%
From $4.48 to $4.86 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

160th out of 985 stocks

Pharmaceutical Preparations Industry

63rd out of 477 stocks

3.3

Analyst's Opinion

Consensus Rating
Sanofi has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $94.50, Sanofi has a forecasted upside of 75.5% from its current price of $53.86.
Amount of Analyst Coverage
Sanofi has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.14% of the float of Sanofi has been sold short.
Short Interest Ratio / Days to Cover
Sanofi has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

2.5

Dividend Strength

Dividend Yield
Sanofi pays a meaningful dividend of 2.31%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Sanofi has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Sanofi is 45.16%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Sanofi will have a dividend payout ratio of 25.93% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNY.

1.8

News and Social Media Coverage

News Sentiment
Sanofi has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Sanofi this week, compared to 8 articles on an average week.
Search Interest
Only 12 people have searched for SNY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sanofi insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Sanofi is held by insiders.
Percentage Held by Institutions
Only 10.04% of the stock of Sanofi is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Sanofi are expected to grow by 8.48% in the coming year, from $4.48 to $4.86 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sanofi is 19.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.41.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sanofi is 19.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.71.
Price to Earnings Growth Ratio
Sanofi has a PEG Ratio of 1.78. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Sanofi has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sanofi (NASDAQ:SNY) Stock

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Stock News Headlines

May 18, 2023 | marketbeat.com

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (SNY)

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

May 5, 2023 | marketbeat.com

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales (SNY)

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

May 18, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Software" to Revolutionize Warfare

This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>

May 18, 2023 | seekingalpha.com

Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron

May 18, 2023 | investing.com

U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents

May 18, 2023 | msn.com

Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron

May 18, 2023 | finance.yahoo.com

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi

May 16, 2023 | thestreet.com

Buy Warren Buffett's 5 Highest-Yielding Dividend Stocks for Income Now

May 18, 2023 | Legacy Research (Affiliate) (Ad)

Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast

He predicted the 2020 crash a month before it happened… He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.

May 15, 2023 | benzinga.com

Peering Into Sanofi's Recent Short Interest

May 13, 2023 | realmoney.thestreet.com

These 3 Global Drug Stocks Have a Prescription for High Yields

May 13, 2023 | americanbankingnews.com

Sanofi (NYSE:SNY) Downgraded to Buy at StockNews.com

May 12, 2023 | msn.com

Rebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing

May 12, 2023 | americanbankingnews.com

Head to Head Analysis: TherapeuticsMD (NASDAQ:TXMD) and Sanofi (NASDAQ:SNY)

May 5, 2023 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Receives $100.20 Consensus Price Target from Analysts

May 3, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Sanofi (NASDAQ:SNY) Lowered by SVB Leerink

May 1, 2023 | finance.yahoo.com

Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront

April 29, 2023 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Downgraded by Deutsche Bank Aktiengesellschaft to Sell

April 28, 2023 | finance.yahoo.com

Sanofi (SNY) Q1 2023 Earnings Call Transcript

April 27, 2023 | finance.yahoo.com

Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales

April 25, 2023 | americanbankingnews.com

Sanofi (SNY) Scheduled to Post Earnings on Thursday

April 23, 2023 | markets.businessinsider.com

Sanofi Launches Hepatitis A Vaccine In U.K For Use In Children Aged 12 Months To 15 Yrs

April 21, 2023 | finance.yahoo.com

Sanofi (SNY) is a Great Momentum Stock: Should You Buy?

April 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Sanofi (SNY)

April 18, 2023 | proactiveinvestors.com

Tiziana Life Sciences to develop Foralumab for type 1 diabetes

April 18, 2023 | americanbankingnews.com

Research Analysts Issue Forecasts for Sanofi's FY2025 Earnings (NASDAQ:SNY)

April 18, 2023 | seekingalpha.com

Sanofi: The Growth Engine Is Slowly Picking Up Steam

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Company Calendar

Last Earnings: 4/27/2023
Today: 5/18/2023
Ex-Dividend for 6/23 Dividend: 5/30/2023
Dividend Payable: 6/23/2023
Next Earnings (Estimated): 7/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNY
CUSIP: N/A
CIK: 1121404
Web: www.sanofi.com
Phone: (315) 377-4000
Fax: 33-1-53-77-43-03
Employees: 91,573
Year Founded: 2004

Price Target and Rating

Average Stock Price Forecast: $94.50
High Stock Price Forecast: $119.00
Low Stock Price Forecast: $60.00
Forecasted Upside/Downside: +75.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.79
Trailing P/E Ratio: 19.30
Forward P/E Ratio: 12.02
P/E Growth: 1.78
Net Income: $8.82 billion
Net Margins: 15.41%
Pretax Margin: 24.33%
Return on Equity: 28.45%
Return on Assets: 16.76%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 1.42
Quick Ratio: 1.05

Sales & Book Value

Annual Sales: $45.31 billion
Price / Sales: 3.00
Cash Flow: $5.68 per share
Price / Cash Flow: 9.49
Book Value: $31.40 per share
Price / Book: 1.72

Miscellaneous

Outstanding Shares: 2,521,930,000
Free Float: 2,496,708,000
Market Cap: $135.83 billion
Optionable: Optionable
Beta: 0.57

Social Links

Key Executives

Paul Hudson
Chief Executive Officer & Director

Jean-Baptiste Chasseloup de Chatillon
Chief Financial Officer & Executive Vice President

Nestle Frank
Global Head-Immunology Therapeutic Research Area

Dietmar P. Berger
Chief Medical Officer & Global Head-Development

Natalie Bickford
Chief People Officer & Executive Vice President

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNY Stock - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNY shares.
View SNY analyst ratings or view top-rated stocks.
What is Sanofi's stock price forecast for 2023?: 10 equities research analysts have issued 1-year target prices for Sanofi's stock. Their SNY share price forecasts range from $60.00 to $119.00. On average, they expect the company's share price to reach $94.50 in the next year. This suggests a possible upside of 75.8% from the stock's current price.
View analysts price targets for SNY or view top-rated stocks among Wall Street analysts.
How have SNY shares performed in 2023?: Sanofi's stock was trading at $48.43 at the start of the year. Since then, SNY stock has increased by 11.0% and is now trading at $53.74.
View the best growth stocks for 2023 here.
When is Sanofi's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our SNY earnings forecast.
How were Sanofi's earnings last quarter?: Sanofi (NASDAQ:SNY) announced its quarterly earnings results on Thursday, April, 27th. The company reported $1.16 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.06. The company earned $10.97 billion during the quarter, compared to the consensus estimate of $11.60 billion. Sanofi had a net margin of 15.41% and a trailing twelve-month return on equity of 28.45%.
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?: Sanofi announced an annual dividend on Sunday, May 14th. Stockholders of record on Wednesday, May 31st will be given a dividend of $1.377 per share on Friday, June 23rd. This represents a yield of 2.94%. The ex-dividend date is Tuesday, May 30th.
Read our dividend analysis for SNY.
What ETFs hold Sanofi's stock?: ETFs with the largest weight of Sanofi (NASDAQ:SNY) stock in their portfolio include Pacer BioThreat Strategy ETF (VIRS), VanEck Pharmaceutical ETF (PPH), Subversive Mental Health ETF (SANE), Simplify Health Care ETF (PINK), Horizon Kinetics Medical ETF (MEDX), Invesco International Dividend Achievers ETF (PID), Putnam Focused Large Cap Value ETF (PVAL) and Amplify International Enhanced Dividend Income ETF (IDVO).
Is Sanofi a good dividend stock?: Sanofi (NASDAQ:SNY) pays an annual dividend of $1.26 per share and currently has a dividend yield of 2.31%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 45.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 25.93% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.

What is Paul Hudson's approval rating as Sanofi's CEO?: 277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sanofi own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), AstraZeneca (AZN), AstraZeneca (AZN), Boeing (BA), Alibaba Group (BABA) and Bank of America (BAC).
What is Sanofi's stock symbol?: Sanofi trades on the NASDAQ under the ticker symbol "SNY."
Who are Sanofi's major shareholders?: Sanofi's stock is owned by many different institutional and retail investors. Top institutional investors include Dodge & Cox (3.27%), FMR LLC (0.92%), Boston Partners (0.71%), Fisher Asset Management LLC (0.53%), Bank of America Corp DE (0.42%) and BlackRock Inc. (0.40%).
View institutional ownership trends.
How do I buy shares of Sanofi?: Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sanofi's stock price today?: One share of SNY stock can currently be purchased for approximately $53.74.
How much money does Sanofi make?: Sanofi (NASDAQ:SNY) has a market capitalization of $135.53 billion and generates $45.31 billion in revenue each year. The company earns $8.82 billion in net income (profit) each year or $2.79 on an earnings per share basis.
How many employees does Sanofi have?: The company employs 91,573 workers across the globe.
Does Sanofi have any subsidiaries?: The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More
How can I contact Sanofi?: Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The official website for the company is www.sanofi.com. The company can be reached via phone at (315) 377-4000, via email at ir@sanofi.com, or via fax at 33-1-53-77-43-03.

This page (NASDAQ:SNY) was last updated on 5/18/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial